GI Dynamics lands research partnerships with Medtronic and GlaxoSmithKline, evaluating the relationship between EndoBarrier intestinal liner treatment and patient glucose levels and hormonal changes. Weight loss devices maker GI Dynamics (ASX:GID) announced new research partnerships with GlaxoSmithKline (NYSE:GSK) and Medtronic (NYSE:MDT), looking for new data on its EndoBarrier intestinal liner. The partnership with Medtronic will examine how treatment with EndoBarrier affects continuous glucose levels and the research with GlaxoSmithKline will look at hormonal changes as a result of the implant.